Ucb UCB.BR · EUR

Its shares trade on Euronext Brussels under the ticker UCB.BR. It has been listed since 2 January 1987. In the fiscal year to 31 December 2025, it reported revenue of €7.74bn and net income of €1.56bn. At that date it held total assets of €18.16bn and shareholders' equity of €10.87bn.

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. The company is headquartered in Anderlecht, Bruxelles-Capitale. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Jean-Christophe TellierChief Executive Officer, Chairman of the Executive Committee, Executive Director, since 2011€6.8m
• Mr. Charles-Antoine JanssenNon-Executive Vice Chairman of the Board€138,525
• Ms. Sandrine DufourExecutive Vice President, Chief Financial Officer, Member of the Executive Committee
• Mr. Jean-Luc FleurialExecutive Vice President, Chief Human Resources Officer, Member of the Executive Committee€330,044
• Mr. Alistair HenryExecutive Vice President, Chief Scientific Officer, Member of the Executive Committee
• Ms. Denelle Waynick JohnsonExecutive Vice President, General Counsel, Member of the Executive Committee
• Mr. Emmanuel CaeymaexExecutive Vice President, Chief Commercial Officer, Member of the Executive Committee€515,367
• Ms. Fiona Du MonceauExecutive Vice President - Patient Evidence, Member of the Executive Committee, since 2021€32,839
• Ms. Kirsten Lund-jurgensenExecutive Vice President - Patient Supply, Member of the Executive Committee
• Mr. Xavier MichelGroup Secretary General
• Mr. Cyril JanssenNon-Executive Director€86,000
• Mr. Cedric van RijckevorselNon-Executive Director€103,951

Overall

88

Environment

99

Social

99

Governance

66

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.